Fintech Darling Afterpay: Buy Now, Regret at Leisure? The stock’s meteoric rise looks vulnerable to expanding competition or a prolonged downturn that raises credit risksYesterday in WSJ;
NTI Neurotech knocked back by FDA as agency declares target condition not rare enough for special status